2024
ASO Visual Abstract: Cryoablation without Excision for Early Stage Breast Cancer; ICE3 Trial 5-Year Follow-Up on Ipsilateral Breast Tumor Recurrence
Fine R, Gilmore R, Tomkovich K, Dietz J, Berry M, Hernandez L, Columbus K, Seedman S, Fisher C, Han L, Manahan E, Hicks R, Vaidya R, Curcio L, Sevrukov A, Kenler A, Taback B, Chen M, Miller M, Gold L, Anglin B, Aoun H, Simmons R, Feldman S, Boolbol S. ASO Visual Abstract: Cryoablation without Excision for Early Stage Breast Cancer; ICE3 Trial 5-Year Follow-Up on Ipsilateral Breast Tumor Recurrence. Annals Of Surgical Oncology 2024, 31: 8923-8924. DOI: 10.1245/s10434-024-16272-y.Peer-Reviewed Original ResearchCASCADES, a novel SOX2 super‐enhancer‐associated long noncoding RNA, regulates cancer stem cell specification and differentiation in glioblastoma
Shahzad U, Nikolopoulos M, Li C, Johnston M, Wang J, Sabha N, Varn F, Riemenschneider A, Krumholtz S, Krishnamurthy P, Smith C, Karamchandani J, Watts J, Verhaak R, Gallo M, Rutka J, Das S. CASCADES, a novel SOX2 super‐enhancer‐associated long noncoding RNA, regulates cancer stem cell specification and differentiation in glioblastoma. Molecular Oncology 2024, 19: 764-784. PMID: 39323013, PMCID: PMC11887672, DOI: 10.1002/1878-0261.13735.Peer-Reviewed Original ResearchCancer stem cellsGlioma CSCsPresence of cancer stem cellsCancer stem cell compartmentPrimary malignant brain tumorGlioma cancer stem cellsMalignant brain tumorsCancer-specific mannerMedian survivalTumor recurrenceTreatment resistanceStem cell specificationRegulation of stemnessTumor developmentRegulation of Sox2Brain tumorsNeuronal lineageStem cellsGlioblastomaTherapeutic targetSOX2Cell RepositoryCell-specificTumorLong noncoding RNAsCryoablation Without Excision for Early-Stage Breast Cancer: ICE3 Trial 5-Year Follow-Up on Ipsilateral Breast Tumor Recurrence
Fine R, Gilmore R, Tomkovich K, Dietz J, Berry M, Hernandez L, Columbus K, Seedman S, Fisher C, Han L, Manahan E, Hicks R, Vaidya R, Curcio L, Sevrukov A, Kenler A, Taback B, Chen M, Miller M, Gold L, Anglin B, Aoun H, Simmons R, Feldman S, Boolbol S. Cryoablation Without Excision for Early-Stage Breast Cancer: ICE3 Trial 5-Year Follow-Up on Ipsilateral Breast Tumor Recurrence. Annals Of Surgical Oncology 2024, 31: 7273-7283. PMID: 39283572, PMCID: PMC11452421, DOI: 10.1245/s10434-024-16181-0.Peer-Reviewed Original ResearchIpsilateral breast tumor recurrenceEarly-stage breast cancerBreast tumor recurrenceTumor recurrenceAdverse eventsBreast cancerEpidermal growth factor receptor 2 (HER2)-negativeHuman epidermal growth factor receptor 2 (HER2)-negativeIpsilateral breast tumor recurrence ratesHormone receptor (HR)-positivePatients meeting eligibilityDevice-related adverse eventsNon-operative treatment optionsHistological grade 1Institutional review board approvalPotential surgical risksEfficacy of cryoablationInvasive ductal carcinomaAlternative to surgeryLow-risk patientsPrimary study endpointFollow-up periodMinimally invasive procedureQuality-of-life scoresReview board approvalHealthcare Resource Use Associated With Tumor-Induced Osteomalacia: A Literature Review
de Beur S, Dahir K, Imel E, Zanchetta M, Williams A, Li Z, Webb N, Crowe V, Johnson B, Carpenter T. Healthcare Resource Use Associated With Tumor-Induced Osteomalacia: A Literature Review. The Journal Of Clinical Endocrinology & Metabolism 2024, 110: 102-113. PMID: 38913723, PMCID: PMC11651676, DOI: 10.1210/clinem/dgae431.Peer-Reviewed Original ResearchTumor-induced osteomalaciaHealthcare resource useResection outcomesCase reportHigher probability of tumor recurrenceSecrete fibroblast growth factor 23Probability of tumor recurrenceAssociated with tumor-induced osteomalaciaFibroblast growth factor 23Symptoms to diagnosisHealthcare resource burdenTumor recurrenceParaneoplastic syndromeTumor resectionAssociated with greater usePharmacological treatmentDisease characteristicsImaging testsPatientsMusculoskeletal symptomsTargeted literature reviewResource useOrthopedic surgeryProgressive disabilityMean timeStrategically Staged Tumor Ablation and Inflammation Suppression Using Shell‐Core Nanoparticles to Eradicate Bladder Tumors and Prevent Recurrence
Xu Y, Zhang R, Zhu J, Guo Z, Jin D, Qian L, Yang Y, Chen H. Strategically Staged Tumor Ablation and Inflammation Suppression Using Shell‐Core Nanoparticles to Eradicate Bladder Tumors and Prevent Recurrence. Advanced Functional Materials 2024, 34 DOI: 10.1002/adfm.202402078.Peer-Reviewed Original ResearchPrevent tumor recurrenceBladder tumorsTumor recurrenceTumor ablationPreventing bladder tumor recurrenceRat bladder tumor modelBladder tumor modelBladder tumor recurrenceInflammation suppressionCancer-related inflammationRelease of nitric oxideAnti-inflammatory effectsAcidic tumor environmentTumor environmentTumor modelPrevent recurrenceReduce inflammationTumorRecurrenceInflammationReactive oxygen speciesNitric oxideIn vitroAbstract NanomedicineAnti-tumorMultimodality Imaging of Postmastectomy Breast Reconstruction Techniques, Complications, and Tumor Recurrence.
Thai J, Sodagari F, Colwell A, Winograd J, Revzin M, Mahmoud H, Mozayan S, Chou S, Destounis S, Butler R. Multimodality Imaging of Postmastectomy Breast Reconstruction Techniques, Complications, and Tumor Recurrence. RadioGraphics 2024, 44: e230070. PMID: 38573814, DOI: 10.1148/rg.230070.Peer-Reviewed Original ResearchConceptsTumor recurrencePostoperative evaluation of patientsFlap reconstruction methodsImplant-based reconstructionMultimodal imagingBreast reconstruction techniquesFat graft placementBreast cancer recurrenceTissue flap reconstructionEvaluation of patientsNipple-sparing techniquesTissue donor sitesFlap-based reconstructionNipple-areolar complex reconstructionDiagnostic breast imagingUnique patient populationAutologous tissue flapsAbnormal imaging appearancesBreast cancer screeningMastectomy optionLocal recurrenceOncoplastic surgeryDisease recurrenceFlap reconstructionReconstructed breastTh2 Cells Are Associated with Tumor Recurrence Following Radiation
Abdelhakiem M, Bao R, Pifer P, Molkentine D, Molkentine J, Hefner A, Beadle B, Heymach J, Luke J, Ferris R, Pickering C, Wang J, Patel R, Skinner H. Th2 Cells Are Associated with Tumor Recurrence Following Radiation. Cancers 2024, 16: 1586. PMID: 38672668, PMCID: PMC11049347, DOI: 10.3390/cancers16081586.Peer-Reviewed Original ResearchHead and neck squamous cell carcinomaLocoregional recurrenceValidation cohortTh2 infiltrationDiscovery cohortTh2 cellsTreatment of multiple solid tumorsAssociated with locoregional recurrenceNeck squamous cell carcinomaAssociated with tumor recurrencePrognostic immune biomarkersAntitumor immune responseTumor immune infiltrationSquamous cell carcinomaMultiple solid tumorsIndependent validation cohortResponse to radiationImmune cell typesMechanism of radiation resistanceAssociated with outcomeAdjuvant radiationTumor recurrenceHNSCC tumorsCell carcinomaImmune infiltrationProgrammable Bacteria‐Based Biohybrids as Living Biotherapeutics for Enhanced Cancer Sonodynamic‐Immunotherapy
Wang C, Chen L, Zhu J, Wang C, Li M, Miao Y, Liu N, Ji Z, Pan F, Liu Y, Zhu J, Yang Y, Chen Q. Programmable Bacteria‐Based Biohybrids as Living Biotherapeutics for Enhanced Cancer Sonodynamic‐Immunotherapy. Advanced Functional Materials 2024, 34 DOI: 10.1002/adfm.202316092.Peer-Reviewed Original ResearchSonodynamic therapyAntitumor immune responseTumor-associated antigensImmune memory responsePrevent tumor recurrenceInhibit tumor metastasisOrthotopic colorectal tumorsAbscopal effectTumor recurrenceEffective sonodynamic therapyTumor siteNano-sonosensitizersTumor hypoxiaPathogen-associated molecular patternsColorectal tumorsMemory responsesTherapeutic delivery systemsTumor metastasisImmune responseTumorLive biotherapeuticsMetastasisBacterial pathogen-associated molecular patternsMolecular patternsOverexpressing catalase
2023
Actin Alpha 2, Smooth Muscle (ACTA2) Is Involved in the Migratory Potential of Malignant Gliomas, and Its Increased Expression at Recurrence Is a Significant Adverse Prognostic Factor
Hoshimaru T, Nonoguchi N, Kosaka T, Furuse M, Kawabata S, Yagi R, Kurisu Y, Kashiwagi H, Kameda M, Takami T, Kataoka-Sasaki Y, Sasaki M, Honmou O, Hiramatsu R, Wanibuchi M. Actin Alpha 2, Smooth Muscle (ACTA2) Is Involved in the Migratory Potential of Malignant Gliomas, and Its Increased Expression at Recurrence Is a Significant Adverse Prognostic Factor. Brain Sciences 2023, 13: 1477. PMID: 37891844, PMCID: PMC10605410, DOI: 10.3390/brainsci13101477.Peer-Reviewed Original ResearchActin alpha 2Malignant gliomasDistant recurrenceACTA2 expressionKD groupSmooth muscleSignificant adverse prognostic factorMode of recurrenceAlpha 2Progression-free survivalAdverse prognostic factorHuman malignant glioma cell linesMalignant glioma cell linesClinical glioma samplesGlioma cell linesPrognostic factorsBrain invasionTumor recurrenceInvasive tumorsNovel therapiesGlioma patientsSame patientRecurrenceControl groupPotential biomarkersCancer immunotherapy with enveloped self-amplifying mRNA CARG-2020 that modulates IL-12, IL-17 and PD-L1 pathways to prevent tumor recurrence
Chen J, Madina B, Ahmadi E, Yarovinsky T, Krady M, Meehan E, Wang I, Ye X, Pitmon E, Ma X, Almassian B, Nakaar V, Wang K. Cancer immunotherapy with enveloped self-amplifying mRNA CARG-2020 that modulates IL-12, IL-17 and PD-L1 pathways to prevent tumor recurrence. Acta Pharmaceutica Sinica B 2023, 14: 335-349. PMID: 38261838, PMCID: PMC10792965, DOI: 10.1016/j.apsb.2023.08.034.Peer-Reviewed Original ResearchCancer immunotherapyTumor recurrenceShort hairpin RNASurvival benefitIL-12Immune mechanismsLong-term survival benefitIL-17 receptor ACancer-promoting inflammationLarge established tumorsMultiple immune mechanismsPD-L1 pathwayT cell exhaustionDeath ligand 1Human cancer immunotherapySelf-amplifying mRNATumor-bearing miceVirus-like vesiclesMechanism of protectionCombined immunomodulationContralateral tumorsIL-17Established tumorsAbscopal effectImmunological memoryKRAS mutation in primary ovarian serous borderline tumors correlates with tumor recurrence
McHenry A, Rottmann D, Buza N, Hui P. KRAS mutation in primary ovarian serous borderline tumors correlates with tumor recurrence. Virchows Archiv 2023, 483: 71-79. PMID: 37219599, DOI: 10.1007/s00428-023-03564-z.Peer-Reviewed Original ResearchConceptsOvarian serous borderline tumorsSerous borderline tumorsNon-invasive implantsDisease-free survivalKRAS mutationsTumor recurrenceExtraovarian implantsAdverse disease-free survivalWorse disease-free survivalHigher stage diseaseKRAS mutation testingHigher tumor stageWild-type KRASBRAF V600E mutationBRAF mutational analysisBorderline tumorsClinical outcomesHistological subtypesTumor stageBRAF mutationsUseful biomarkerInvasive implantsTumors correlatesV600E mutationMutational status
2022
The Role of Surgical Approaches in the Multi-Modal Management of Adult Craniopharyngiomas
Hong CS, Omay SB. The Role of Surgical Approaches in the Multi-Modal Management of Adult Craniopharyngiomas. Current Oncology 2022, 29: 1408-1421. PMID: 35323318, PMCID: PMC8947636, DOI: 10.3390/curroncol29030118.Peer-Reviewed Original ResearchConceptsSurgical approachBenign primary brain tumorsAggressive surgical resectionAdjuvant radiation therapyOptimal surgical approachInvasive surgical approachPrimary brain tumorsSurgical treatment paradigmMulti-modal managementEloquent neural structuresEndoscopic endonasal approachBenign biologyClinical sequelaeHypothalamic dysfunctionOpen resectionSurgical resectionSignificant morbidityOptic apparatusSafe resectionTumor recurrenceTranscranial surgeryTreatment paradigmDisease entityHypothalamic functionLateral approachCombination laser interstitial thermal therapy plus stereotactic radiotherapy increases time to progression for biopsy-proven recurrent brain metastases
Grabowski MM, Srinivasan ES, Vaios EJ, Sankey EW, Otvos B, Krivosheya D, Scott A, Olufawo M, Ma J, Fomchenko EI, Herndon JE, Kim AH, Chiang VL, Chen CC, Leuthardt EC, Barnett GH, Kirkpatrick JP, Mohammadi AM, Fecci PE. Combination laser interstitial thermal therapy plus stereotactic radiotherapy increases time to progression for biopsy-proven recurrent brain metastases. Neuro-Oncology Advances 2022, 4: vdac086. PMID: 35795470, PMCID: PMC9248774, DOI: 10.1093/noajnl/vdac086.Peer-Reviewed Original ResearchLaser interstitial thermal therapyRecurrent brain metastasesBrain metastasis recurrenceKarnofsky performance statusBrain metastasesStereotactic radiotherapyLesion progressionInterstitial thermal therapyMetastasis recurrenceEfficacy of LITTNeuro-Oncology Brain Metastases criteriaSRT failurePercent of patientsAcademic medical centerContrast-enhancing volumeMetastasis (TNM) criteriaOpen resectionPerformance statusProspective trialMedian timeRetrospective studyTumor recurrenceInclusion criteriaMedical CenterEffective treatment
2021
Unusual complications after MammoSite brachytherapy: out‐of‐field rib fracture and Mondor's disease
Rahimy E, Evans S. Unusual complications after MammoSite brachytherapy: out‐of‐field rib fracture and Mondor's disease. Precision Radiation Oncology 2021, 5: 205-207. DOI: 10.1002/pro6.1128.Peer-Reviewed Original ResearchRib fracturesMondor's diseaseMammoSite brachytherapyRare clinical entityPartial breast irradiationMaximum point doseRare complicationBreast irradiationClinical entityTumor recurrenceUnusual complicationRisk factorsPrescribed doseRadiation oncologistsDiseasePoint doseComplicationsFirst caseRecent reportsBrachytherapyDoseAbstract Recent reportsFracturesRecurrenceOncologistsMetastatic perioral melanoma in a wild mountain gorilla (Gorilla beringei beringei)
Syaluha E, Zimmerman D, Ramer J, Gilardi K, Kabuyaya M, Cranfield MR, Kent MS, Corner SM, Yeh N, Lowenstine L. Metastatic perioral melanoma in a wild mountain gorilla (Gorilla beringei beringei). Journal Of Medical Primatology 2021, 50: 197-200. PMID: 33893639, DOI: 10.1111/jmp.12521.Peer-Reviewed Original ResearchConceptsMelanoma vaccineTumor recurrenceMalignant melanomaMelanomaRecurrenceMetastasisLungVaccineKidneyLiverAn integrated model of N6-methyladenosine regulators to predict tumor aggressiveness and immune evasion in pancreatic cancer
Zhou Z, Zhang J, Xu C, Yang J, Zhang Y, Liu M, Shi X, Li X, Zhan H, Chen W, McNally L, Fung K, Luo W, Houchen C, He Y, Zhang C, Li M. An integrated model of N6-methyladenosine regulators to predict tumor aggressiveness and immune evasion in pancreatic cancer. EBioMedicine 2021, 65: 103271. PMID: 33714027, PMCID: PMC7966986, DOI: 10.1016/j.ebiom.2021.103271.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsPancreatic ductal adenocarcinomaImmune evasionCheckpoint inhibitorsOverall survivalImmune infiltrationPancreatic cancerTumor aggressivenessM6A regulatorsSomatic copy number alterationsT cell exhaustionDismal overall survivalMutation profilesN6-methyladenosine regulatorsHigh response ratePancreatic cancer prognosisClassical pancreatic ductal adenocarcinomaCancer CenterColorectal cancerTumor recurrenceDuctal adenocarcinomaM6AscoreBreast cancerTreatment responseCell exhaustion
2020
Associations of meningioma molecular subgroup and tumor recurrence
Youngblood MW, Miyagishima DF, Jin L, Gupte T, Li C, Duran D, Montejo JD, Zhao A, Sheth A, Tyrtova E, Özduman K, Iacoangeli F, Peyre M, Boetto J, Pease M, Avşar T, Huttner A, Bilguvar K, Kilic T, Pamir MN, Amankulor N, Kalamarides M, Erson-Omay EZ, Günel M, Moliterno J. Associations of meningioma molecular subgroup and tumor recurrence. Neuro-Oncology 2020, 23: 783-794. PMID: 33068421, PMCID: PMC8099468, DOI: 10.1093/neuonc/noaa226.Peer-Reviewed Original ResearchConceptsDivergent clinical coursesMolecular subgroupsClinical courseClinical outcomesProgression-free survivalExtent of resectionKaplan-Meier analysisLong-term outcomesLow-grade tumorsCox proportional hazardsDistinct clinical outcomesPostoperative radiationIndependent predictorsMale sexRecurrence rateSurveillance imagingTumor recurrencePrevious recurrencesClinical prognosticationKi-67Outcome dataAggressive subgroupRecurrenceElevated recurrenceProportional hazardsMRI surveillance following concurrent cochlear implantation in cases of vestibular schwannoma resection
Schwartz N, Rooth MA, Dillon MT, O'Connell BP, Dedmon MM, Huang BY, Brown KD. MRI surveillance following concurrent cochlear implantation in cases of vestibular schwannoma resection. American Journal Of Otolaryngology 2020, 41: 102518. PMID: 32451290, DOI: 10.1016/j.amjoto.2020.102518.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overCochlear ImplantationCochlear NerveCranial Nerve NeoplasmsFemaleFollow-Up StudiesHumansMagnetic Resonance ImagingMaleMiddle AgedMonitoring, PhysiologicNeuroma, AcousticOrgan Sparing TreatmentsPostoperative PeriodRetrospective StudiesVestibulocochlear NerveVestibulocochlear Nerve DiseasesConceptsInternal auditory canalConcurrent cochlear implantationVestibular schwannoma resectionIpsilateral internal auditory canalCerebellopontine angleSchwannoma resectionCochlear nerveCochlear implantationHead MRITranslabyrinthine vestibular schwannoma resectionCochlear implant magnetResidual tumor growthCI recipientsMagnetic resonance imaging (MRI) monitoringTranslabyrinthine excisionImplant magnetMRI surveillanceRetrospective reviewVS tumorsTumor recurrenceAuditory canalSerial monitoringCI magnetExcellent visualizationTumor growth[11C]Methionine and [11C]PBR28 as PET Imaging Tracers to Differentiate Metastatic Tumor Recurrence or Radiation Necrosis
Tran TT, Gallezot JD, Jilaveanu LB, Zito C, Turcu G, Lim K, Nabulsi N, Huang H, Huttner A, Kluger HM, Chiang VL, Carson R. [11C]Methionine and [11C]PBR28 as PET Imaging Tracers to Differentiate Metastatic Tumor Recurrence or Radiation Necrosis. Molecular Imaging 2020, 19: 1536012120968669. PMID: 33147119, PMCID: PMC7649862, DOI: 10.1177/1536012120968669.Peer-Reviewed Original ResearchConceptsRadiation necrosisTumor regrowthStereotactic radiosurgeryBrain metastasesPET tracersHigh amino acid uptakeMetastatic tumor recurrenceLung cancer cellsSpecific PET tracersPET imaging tracerTumor recurrenceAmino acid uptakeImaging tracerReliable markerDiagnostic imagingLack of specificityAcid uptakeCancer cellsSpecific markersMethionine levelsTranslocator proteinSequential imagingInflammationMetastasisDual tracer
2019
BMP signaling mediates glioma stem cell quiescence and confers treatment resistance in glioblastoma
Sachdeva R, Wu M, Johnson K, Kim H, Celebre A, Shahzad U, Graham M, Kessler J, Chuang J, Karamchandani J, Bredel M, Verhaak R, Das S. BMP signaling mediates glioma stem cell quiescence and confers treatment resistance in glioblastoma. Scientific Reports 2019, 9: 14569. PMID: 31602000, PMCID: PMC6787003, DOI: 10.1038/s41598-019-51270-1.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic AgentsBone Morphogenetic Protein 4Bone Morphogenetic ProteinsBrain NeoplasmsCell DivisionCell Line, TumorCell ProliferationDisease ProgressionDrug Resistance, NeoplasmGlioblastomaGliomaHomeostasisHumansMiceMice, Inbred NODNeoplasm Recurrence, LocalNeoplasm TransplantationNeoplastic Stem CellsPhenotypeRNA, Small InterferingSequence Analysis, RNASignal TransductionTemozolomideTransforming Growth Factor betaTransforming Growth Factor beta1ConceptsBMP pathway activationStem cell homeostasisStem cell systemStem cell quiescenceStem cell populationCancer stem cell populationInhibits cell proliferationStem-like cellsCancer stem cellsCell quiescenceCell homeostasisFunctional identityDismal prognosisTemozolomide chemotherapyCytotoxic therapyTumor recurrenceCellular reservoirsTreatment resistanceTherapeutic resistanceIncurable diseaseTumor progressionStem cellsCell proliferationPathway activationGlioblastoma
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply